Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-01-18
2010-02-16
Haddad, Maher M (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388220, C530S388700, C530S391100, C424S130100, C424S133100, C424S136100, C424S144100
Reexamination Certificate
active
07662926
ABSTRACT:
The present application describes antibodies that selectively bind human FcγRIIB, with little or no binding to other human FcγRs, e.g., human FcγRIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds FcγRIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.
REFERENCES:
patent: 4515893 (1985-05-01), Kung et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5091313 (1992-02-01), Chang
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5714338 (1998-02-01), Fei et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 7138494 (2006-11-01), Endou et al.
patent: 2006/0193857 (2006-08-01), Boruchov et al.
patent: 0 420 937 (1994-11-01), None
patent: 93/04173 (1993-03-01), None
patent: 95/19181 (1995-07-01), None
patent: 95/23865 (1995-09-01), None
patent: 96/30046 (1996-10-01), None
patent: 96/40210 (1996-12-01), None
patent: 97/26912 (1997-07-01), None
patent: 98/06248 (1998-02-01), None
patent: 98/23761 (1998-06-01), None
patent: 98/45331 (1998-10-01), None
patent: 98/51793 (1998-11-01), None
patent: 99/01556 (1999-01-01), None
patent: 00/29431 (2000-05-01), None
patent: 00/75348 (2000-12-01), None
patent: 01/40309 (2001-06-01), None
patent: 01/79299 (2001-10-01), None
patent: 02/088317 (2002-11-01), None
patent: 02/102320 (2002-12-01), None
patent: 03/066095 (2003-08-01), None
patent: 2004/016750 (2004-02-01), None
patent: 2005/018669 (2005-03-01), None
patent: 2005/110474 (2005-11-01), None
patent: 2005/115452 (2005-12-01), None
patent: 2006/066078 (2006-06-01), None
Berg et al., “Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain”Proc. Natl. Acad. Sci. USA88:4723-4727 (Jun. 1991).
Bubnoff, D. et al., “The central role of FcεRI in allergy”Clinical&Experimental Dermatology28(2):184-187 (2003).
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89(10):4285-4289 (May 1992).
Ceriani et al., “Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms”Cancer Research55(23):5852s-5856s (1995).
Chamow et al., “A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+Effectors to Kill HIV-1-Infected Cells”Journal of Immunology153(9):4268-4280 (Nov. 1, 1994).
Choy et al., “Percentage of anti-cd4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with cilnical improvement”Arthritis Rheum. 39:52-56 (1996).
Clynes et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma”Proc. Natl. Acad. Sci. USA95(2):652-656 (Jan. 1998).
Clynes et al., “Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors”Journal of Experimental Medicine189(1):179-185 (Jan. 4, 1999).
Daeron, M. et al., “Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors”J. Clin. Invest. 95:577-585 (1995).
Daeron, M. et al., “The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation”Immunity3:635-646 (1995).
Dhainaut et al., “CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock”Crit. Care Med. 23(9):1461-1469 (1995).
Ellis et al., “Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma”European Journal of Immunology155:925-937 (1995).
Graziano et al., “Construction and characterization of a humanized anti-γ-Ig receptor Type I (FcγRI) monoclonal antibody”J. Immunol. 155(10):4996-5002 (1995).
Greenman et al., “Characterization of a new monoclonal anti-FcγRII antibody, AT10, and its incorporation into a biscpecific f(ab′)2derivative for recruitment of cytotoxic effectors”Molecular Immunology28:1243-1254 (1991).
Hourmant et al., “Administration of an Anti-CDlla Monoclonal Antibody in Recipients of Kidney Transplantation”Transplantation58(3):377-380 (Aug. 1994).
Ierino et al., “Mapping epitopes of human FCγRII (CDw32) with monoclonal antibodies and recombinant receptors”J. Immunol. 150:1794-1803 (1993).
Jurcic et al., “Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias”Cancer Research55:5908s-5910s (1995).
Juweid et al., “Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody”Cancer Research55(23 Suppl):5899s-5907s (1995).
Kepley et al., “Co-aggregation of FcγRII with FcεRI on Human Mast Cells Inhibits Antigen-induced Secretion and Involves SHIP-Grb2-Dok Complexes”The Journal of Biological Chemistry279(34):35139-35149 (Aug. 2004).
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”Growth Factors7(1):53-64 (1992).
Litton et al., “Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma”European Journal of Immunology26:1-9 (1996).
Looney, J. R. et al., “Human monocytes and U937 cells bear two distinct Fc receptors for IgG1”J. Immunol. 136:1641-1647 (1986).
Lorenz, H. et al., “In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis”J. Immunol. 156:1646-1653 (1996).
Lyden, T.W. et al., “The Fc receptor for IgG expressed in the villus endothelium of human placenta is FcγRIIb21”J. Immunol. 166:3882-3889 (2001).
Malbec, O. et al., “Fcε receptor I-associated lyn-dependent phosphorylation of Fcγ receptor IIB during negative regulation of mast cell activation”J. Immunol. 160:1647-1658 (1998).
Mantzioris, B.X. et al., “Expression of the Fc receptor for IgG (FcγRII/CD332) by human circulating T and B lymphocytes”J. Immunol. 150:5175-5184 (1993).
Merchant et al., “An efficient route to human bispecific IgG”Nature Biotechnology16(7):677-681 (1998).
Morgenstern, J.P. et al., “Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line”Nucleic Acid Research8:3587-3596 (1990).
Morrison et al., “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains”Proc. Natl. Acad. Sci. USA81(21):6851-6855 (Nov. 1984).
Ono et al., “Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB”Nature383(6597):263-266 (Sep. 19, 1996).
Presta et al., “Humanization of an Antibody Directed Against IgE”J. Immunol. 151(5):2623-2632 (Sep. 1, 1993).
Pulford et al., “A new monoclonal antibody (KB61) recognizing a novel antigen which is selec
Chan Andrew C.
Shields Robert L.
Wu Lawren
Dahle Chun
Genentech Inc.
Genentech, Inc.
Haddad Maher M
Svoboda Craig G.
LandOfFree
Anti-Fc-gamma receptor antibodies, bispecific variants and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-Fc-gamma receptor antibodies, bispecific variants and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-Fc-gamma receptor antibodies, bispecific variants and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197068